» Articles » PMID: 24278698

Membrane Transporters As Mediators of Cisplatin Effects and Side Effects

Overview
Publisher Wiley
Specialty Biology
Date 2013 Nov 27
PMID 24278698
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Transporters are important mediators of specific cellular uptake and thus, not only for effects, but also for side effects, metabolism, and excretion of many drugs such as cisplatin. Cisplatin is a potent cytostatic drug, whose use is limited by its severe acute and chronic nephro-, oto-, and peripheral neurotoxicity. For this reason, other platinum derivatives, such as carboplatin and oxaliplatin, with less toxicity but still with antitumoral action have been developed. Several transporters, which are expressed on the cell membranes, have been associated with cisplatin transport across the plasma membrane and across the cell: the copper transporter 1 (Ctr1), the copper transporter 2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, the organic cation transporter 2 (OCT2), and the multidrug extrusion transporter 1 (MATE1). Some of these transporters are also able to accept other platinum derivatives as substrate. Since membrane transporters display a specific tissue distribution, they can be important molecules that mediate the entry of platinum derivatives in target and also nontarget cells possibly mediating specific effects and side effects of the chemotherapeutic drug. This paper summarizes the literature on toxicities of cisplatin compared to that of carboplatin and oxaliplatin and the interaction of these platinum derivatives with membrane transporters.

Citing Articles

Lebanese Cannabis sativa L. extract protects from cisplatin-induced nephrotoxicity in mice by inhibiting podocytes apoptosis.

Khalil A, Al Toufaily S, Shebaby W, Hage M, Mroue D, Faour W J Cannabis Res. 2025; 7(1):3.

PMID: 39819647 PMC: 11737194. DOI: 10.1186/s42238-025-00260-4.


Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.

Thompson L, Joy M J Pharmacol Exp Ther. 2024; 391(3):399-414.

PMID: 39322416 PMC: 11585315. DOI: 10.1124/jpet.124.002287.


Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.

Zheng Y, Tang M, Deng Z, Cai P Front Pharmacol. 2024; 15:1445328.

PMID: 39234108 PMC: 11371761. DOI: 10.3389/fphar.2024.1445328.


An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.

Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M Int J Mol Sci. 2024; 25(16).

PMID: 39201255 PMC: 11354135. DOI: 10.3390/ijms25168568.


Autophagy-mediated ID1 turnover dictates chemo-resistant fate in ovarian cancer stem cells.

Phadte P, Bishnu A, Dey P, M M, Mehrotra M, Singh P J Exp Clin Cancer Res. 2024; 43(1):222.

PMID: 39123206 PMC: 11316295. DOI: 10.1186/s13046-024-03147-z.


References
1.
McKeage M, Hsu T, Screnci D, Haddad G, Baguley B . Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer. 2001; 85(8):1219-25. PMC: 2375155. DOI: 10.1054/bjoc.2001.2024. View

2.
Rybak L, Ramkumar V . Ototoxicity. Kidney Int. 2007; 72(8):931-5. DOI: 10.1038/sj.ki.5002434. View

3.
Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

4.
Fillastre J . Cisplatin nephrotoxicity. Toxicol Lett. 1989; 46(1-3):163-75. DOI: 10.1016/0378-4274(89)90125-2. View

5.
Blair B, Larson C, Adams P, Abada P, Pesce C, Safaei R . Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2010; 79(1):157-66. PMC: 3014285. DOI: 10.1124/mol.110.068411. View